Xinvento
ExitedXinvento aims to alleviate the difficulties associated with Congenital Hyperinsulinism (CHI) by developing an effective treatment to overcome the current difficulties of limited effective treatment options available to patients.
Xinvento has 1 recorded funding round in the Tech.eu database (amounts undisclosed). Based in Amsterdam, Netherlands; active in Healthtech. Acquired by Rhythm Pharmaceuticals in 2023. Data as of 28 Oct 2026.
Amsterdam, Netherlandsxinvento.com ↗
Total raised
€0
€0
Funding rounds
1
Investors
8
distinct backers
Active since
2022-04
latest 2022-04
Funding by year
EUR raised per yearXinvento — funding by year — interactive chart.
Data table
| Xinvento — funding by year | |
|---|---|
| 2022 | €0 |
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-04-26 | Seed | — | Daniel de Boer,David Meeker,Dinko Valerio,Ed Kaye,Hans Schikan,James Shannon+2 more | View deal → |
Exit
Type
acquisition
Date
Mar 2023
Value
—
Acquiror
Rhythm Pharmaceuticals (Netherlands)
Investors
8Related news
- Rhythm Pharmaceuticals BV acquires Amsterdam’s Xinvento to develop therapies for congenital hyperinsulinismsiliconcanals.com · 2023-03
- Xinvento Raises Seed Fundingfinsmes.com · 2022-04
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Picnic€1.7BNetherlands · E-commerce
- Just Eat Takeaway€1.6BNetherlands · Foodtech
- Nebius€1.5BNetherlands · Cloud
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData